FI972703L - Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia - Google Patents

Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia Download PDF

Info

Publication number: FI972703L
Authority: FI; Finland
Prior art keywords: recombinant; treating; related diseases; antagonists useful; antagonists
Prior art date: 1994-12-23

Application number

FI972703A

Other languages

English (en)

Swedish (sv)

Other versions

FI972703A0 (fi

FI119374B (fi

Inventor

Robert S Ames

Edward Robert Appelbaum

Irwin M Chaiken

Richard M Cook

Mitchell Stuart Gross

Stephen Dudley Holmes

Lynette Jane Mcmillan

Timothy Wayne Theisen

Original Assignee

Smithkline Beecham Corp

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-23

Filing date

1997-06-23

Publication date

1997-08-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27408594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI972703(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-06 Priority claimed from US08/470,110 external-priority patent/US5693323A/en

1997-06-23 Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp

1997-06-23 Publication of FI972703A0 publication Critical patent/FI972703A0/fi

1997-08-22 Publication of FI972703L publication Critical patent/FI972703L/fi

2008-10-31 Application granted granted Critical

2008-10-31 Publication of FI119374B publication Critical patent/FI119374B/fi

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Pathology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Tropical Medicine & Parasitology (AREA)

FI972703A 1994-12-23 1997-06-23 Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia FI119374B (fi)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
US36313194A	1994-12-23	1994-12-23
US36313194		1994-12-23
US08/470,110 US5693323A (en)	1994-12-23	1995-06-06	Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/467,420 US5683892A (en)	1994-12-23	1995-06-06	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US46742095		1995-06-06
US47011095		1995-06-06
US9517082		1995-12-22
PCT/US1995/017082 WO1996021000A2 (en)	1994-12-23	1995-12-22	Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders

Publications (3)

Publication Number	Publication Date
FI972703A0 FI972703A0 (fi)	1997-06-23
FI972703L true FI972703L (fi)	1997-08-22
FI119374B FI119374B (fi)	2008-10-31

Family

ID=27408594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI972703A FI119374B (fi)	1994-12-23	1997-06-23	Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia

Country Status (21)

Country	Link
US (1)	US6129913A (fi)
EP (1)	EP0800536B1 (fi)
JP (2)	JP2001523083A (fi)
CN (1)	CN100391977C (fi)
AT (1)	ATE346867T1 (fi)
AU (1)	AU708951B2 (fi)
BR (1)	BR9510499B1 (fi)
CA (1)	CA2208503C (fi)
CZ (1)	CZ297045B6 (fi)
DE (1)	DE69535319T2 (fi)
DK (1)	DK0800536T3 (fi)
ES (1)	ES2277336T3 (fi)
FI (1)	FI119374B (fi)
HU (1)	HU222992B1 (fi)
LU (1)	LU92912I2 (fi)
MX (1)	MX9704779A (fi)
NL (1)	NL300787I1 (fi)
NO (2)	NO324181B1 (fi)
NZ (1)	NZ301916A (fi)
PL (1)	PL194312B1 (fi)
WO (1)	WO1996021000A2 (fi)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5683892A (en) *	1994-12-23	1997-11-04	Smithkline Beecham Corporation	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) *	1994-12-23	1998-07-21	Smithkline Beecham Corporation	Method for treatment and diagnosis of IL-5 mediated disorders
EP2270150B2 (en) *	1999-04-09	2019-08-07	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
US6946292B2 (en) *	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2327830T3 (es) *	2002-03-29	2009-11-04	Schering Corporation	Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
JPWO2003084569A1 (ja)	2002-04-09	2005-08-11	協和醗酵工業株式会社	抗体組成物含有医薬
US20070219117A1 (en) *	2003-10-27	2007-09-20	Medvet Science Pty Ltd	Bidentate motif and methods of use
JP4954709B2 (ja) *	2004-10-28	2012-06-20	協和発酵キリン株式会社	子宮内膜症治療剤
EP2606906A1 (en)	2007-04-30	2013-06-26	GlaxoSmithKline LLC	Methods for administering anti-IL-5 antibodies
JP4335286B2 (ja)	2008-02-08	2009-09-30	ファナック株式会社	部品保護機能を備えたロボット制御装置及びロボット制御方法
CA2719786A1 (en)	2008-03-28	2009-10-01	Glaxosmithkline Llc	Methods of treatment
MA34004B1 (fr) *	2010-01-28	2013-02-01	Glaxo Group Ltd	Protéines de liaison à cd127
PT2654790T (pt)	2010-12-22	2019-05-16	Teva Pharmaceuticals Australia Pty Ltd	Anticorpo modificado com semivida melhorada
KR20240099511A (ko)	2015-08-24	2024-06-28	글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드	생물제약 조성물
CN109195990A (zh) *	2016-03-30	2019-01-11	Musc研究发展基金会	通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
EA201991552A1 (ru) *	2016-12-23	2020-01-09	Сефалон, Инк.	Анти-il-5 антитела
AU2018273174B2 (en)	2017-05-26	2021-10-14	Glaxosmithkline Intellectual Property Development Limited	Biopharmaceutical compositions and related methods
MX2020003034A (es) *	2017-09-29	2020-07-22	Jiangsu Hengrui Medicine Co	Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.
CN109942706A (zh) *	2017-12-21	2019-06-28	三生国健药业（上海）股份有限公司	结合人il-5的单克隆抗体、其制备方法和用途
CN111303284A (zh) *	2018-12-12	2020-06-19	尚华科创投资管理（江苏）有限公司	抗人白细胞介素5(il-5)单克隆抗体及其应用
BR112021019272A2 (pt) *	2019-03-29	2022-01-04	Jiangsu Hengrui Medicine Co	Composição farmacêutica contendo anticorpo contra il-5 e uso da mesma
TW202535949A (zh)	2023-12-20	2025-09-16	美商必治妥美雅史谷比公司	靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8800397D0 (en) *	1988-01-08	1988-02-10	Sandoz Ltd	Improvements in/relating to organic compounds
US5096704A (en) *	1988-11-03	1992-03-17	Schering Corporation	Method of treating eosinophilia
ZA898322B (en) *	1988-11-03	1990-11-28	Schering Corp	Method of preventing or reducing eosinophilia
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ZA929328B (en) *	1991-12-02	1993-07-20	Fluor Corp	Apparatus and method for economic use of excess compressed air when firing low caloric-value gas in a combustion gas turbine.
IL104620A (en) *	1992-02-06	2000-02-29	Schering Plough Corp	Humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) *	1992-11-05	1994-05-24	Chemo Sero Therapeut Res Inst	モノクローナル抗体
AU1289795A (en) *	1993-11-19	1995-06-06	Baylor College Of Medicine	Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) *	1994-06-17	1994-08-10	Celltech Ltd	Interleukin-5 specific recombiant antibodies
US5683892A (en) *	1994-12-23	1997-11-04	Smithkline Beecham Corporation	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) *	1994-12-23	1998-07-21	Smithkline Beecham Corporation	Method for treatment and diagnosis of IL-5 mediated disorders
WO2001012646A1 (en) *	1999-08-19	2001-02-22	Smithkline Beecham Corporation	Sialoadhesin factor-1 agonist and antagonist antibodies

1995
- 1995-12-22 EP EP95944692A patent/EP0800536B1/en not_active Expired - Lifetime
- 1995-12-22 JP JP52118996A patent/JP2001523083A/ja not_active Withdrawn
- 1995-12-22 CN CNB951977016A patent/CN100391977C/zh not_active Expired - Lifetime
- 1995-12-22 HU HU9901120A patent/HU222992B1/hu active Protection Beyond IP Right Term
- 1995-12-22 DK DK95944692T patent/DK0800536T3/da active
- 1995-12-22 ES ES95944692T patent/ES2277336T3/es not_active Expired - Lifetime
- 1995-12-22 NZ NZ301916A patent/NZ301916A/xx not_active IP Right Cessation
- 1995-12-22 CZ CZ0196397A patent/CZ297045B6/cs not_active IP Right Cessation
- 1995-12-22 BR BRPI9510499-2A patent/BR9510499B1/pt active IP Right Grant
- 1995-12-22 DE DE69535319T patent/DE69535319T2/de not_active Expired - Lifetime
- 1995-12-22 AU AU47450/96A patent/AU708951B2/en not_active Expired
- 1995-12-22 MX MX9704779A patent/MX9704779A/es unknown
- 1995-12-22 PL PL95321088A patent/PL194312B1/pl unknown
- 1995-12-22 CA CA002208503A patent/CA2208503C/en not_active Expired - Lifetime
- 1995-12-22 WO PCT/US1995/017082 patent/WO1996021000A2/en not_active Ceased
- 1995-12-22 AT AT95944692T patent/ATE346867T1/de active
- 1995-12-22 US US08/637,647 patent/US6129913A/en not_active Expired - Lifetime
1997
- 1997-06-20 NO NO19972913A patent/NO324181B1/no not_active IP Right Cessation
- 1997-06-23 FI FI972703A patent/FI119374B/fi not_active IP Right Cessation
2007
- 2007-10-16 JP JP2007269236A patent/JP2008029355A/ja not_active Withdrawn
2015
- 2015-12-16 LU LU92912C patent/LU92912I2/xx unknown
- 2015-12-18 NL NL300787C patent/NL300787I1/nl unknown
- 2015-12-18 NO NO2015027C patent/NO2015027I2/no unknown

Also Published As

Publication number	Publication date
CA2208503A1 (en)	1996-07-11
EP0800536A2 (en)	1997-10-15
NO2015027I2 (no)	2016-01-04
JP2008029355A (ja)	2008-02-14
EP0800536A4 (en)	2004-12-01
ATE346867T1 (de)	2006-12-15
NO2015027I1 (no)	2015-12-18
BR9510499A (pt)	1999-03-30
DK0800536T3 (da)	2007-04-02
CN1175263A (zh)	1998-03-04
FI972703A0 (fi)	1997-06-23
FI119374B (fi)	2008-10-31
CA2208503C (en)	2009-12-01
WO1996021000A2 (en)	1996-07-11
CZ196397A3 (en)	1997-10-15
PL194312B1 (pl)	2007-05-31
LU92912I2 (fr)	2016-02-16
BR9510499B1 (pt)	2009-05-05
CN100391977C (zh)	2008-06-04
NO324181B1 (no)	2007-09-03
DE69535319D1 (de)	2007-01-11
EP0800536B1 (en)	2006-11-29
AU4745096A (en)	1996-07-24
HK1003651A1 (en)	1998-11-06
NO972913D0 (no)	1997-06-20
NO972913L (no)	1997-08-19
MX9704779A (es)	1997-09-30
NL300787I2 (fi)	2016-04-05
PL321088A1 (en)	1997-11-24
DE69535319T2 (de)	2007-07-19
NL300787I1 (fi)	2016-04-05
JP2001523083A (ja)	2001-11-20
US6129913A (en)	2000-10-10
AU708951B2 (en)	1999-08-19
CZ297045B6 (cs)	2006-08-16
WO1996021000A3 (en)	1996-09-06
NZ301916A (en)	1999-05-28
ES2277336T3 (es)	2007-07-01
HU222992B1 (hu)	2004-01-28
HUT78055A (hu)	1999-07-28

Publication	Publication Date	Title
FI972703L (fi)	1997-08-22	Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
NO982453D0 (no)	1998-05-28	Bar stol
TR199501053A2 (tr)	1996-06-21	Tedavide yararli spiro-azabisiklik bilesikler.
ATE236898T1 (de)	2003-04-15	S-omeprazol in festform
DE69404144D1 (de)	1997-08-14	Bauschiger, stabiler vliesstoff
FI973221L (fi)	1997-10-20	1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
NO974924L (no)	1997-12-19	Modifiserte polypeptider med öket immunogenisitet
NO951345L (no)	1995-10-27	Stolpesko
FI1592U1 (fi)	1994-10-26	Spruta, foeretraedesvis injektionsspruta
FI963664A0 (fi)	1996-09-17	Tuhoamismenetelmä, erityisesti täydellinen polttaminen
IT1268116B1 (it)	1997-02-20	Sedia.
KR960009822U (ko)	1996-04-12	의자
FI2504U1 (fi)	1996-07-19	Tuoli
SE9701730D0 (sv)	1997-05-09	Stol
SE9604136D0 (sv)	1996-11-11	Stol
BR7402231U (pt)	1996-12-31	Aperfeiçoamento em broqueiro
SE9701781D0 (sv)	1997-05-11	Stol
SE9702576D0 (sv)	1997-07-03	Ryggavlastande stol
UA25060C2 (uk)	1998-12-25	Засіб для лікування ендометриту у корів
FI3553U1 (fi)	1998-08-31	Tuoli
SE9801505D0 (sv)	1998-04-29	Stol
ES1028935Y (es)	1995-10-01	Sillon perfeccionado
KR970050777U (ko)	1997-09-08	상ㆍ하ㆍ좌ㆍ우로 이동이 가능한 가구
FI1691U1 (fi)	1995-01-12	Hopsaettningsmaskin foer lastpallsben
KR960016157U (ko)	1996-06-17	다결속 머리핀

Legal Events

Date	Code	Title	Description
2008-10-31	FG	Patent granted	Ref document number: 119374 Country of ref document: FI
2015-12-14	PC	Transfer of assignment of patent	Owner name: GLAXOSMITHKLINE LLC
2015-12-17	SPCF	Supplementary protection certificate application filed	Spc suppl protection certif: C20150067
2015-12-22	SPCG	Supplementary protection certificate granted	Spc suppl protection certif: 440 Extension date: 20201222
2016-01-20	MA	Patent expired